Tumors actively suppress antitumor immunity creating formidable barriers to successful cancer immunotherapy. The molecular mechanisms underlying tumor-induced immune tolerance are largely unknown. In the present study, we show that dendritic cells 
Introduction
Tumors promote immune tolerance, and DCs play an important role in this.
Although the molecular mechanisms of immune suppression by DCs are not fully understood, the ability of DCs to induce and activate regulatory T cells (Treg) is involved (1-5). Retinoic acid (RA), an active metabolite of vitamin A, regulates a broad array of immune responses (6, 7) . Accumulated evidence suggests an important role for RA in immune tolerance in the gut by regulating the functions of antigen presenting cells (APCs), and by promoting the induction and activation of Treg (6, 7) . A recent study has shown that TME contains high levels of RA, and APCs are major producers of RA (8) .
However, its role in Treg induction and activation in response to tumor-induced immune tolerance is not known. Moreover, molecular mechanisms whereby tumors induce APCs to produce RA remain poorly understood. So, we hypothesized that tumors, through DCs, exploit the RA pathway as a mechanism of immune evasion.
β-catenin is a transcriptional co-factor which, upon activation, interacts with several family transcription factors (TFs) such as TCFs (9) , PPARγ (10, 11) , Foxo (12, 13) , VDR (12, 14) , IRF3 (15) etc. Upon interaction with TFs, β-catenin can either promote or suppress the expression of target genes (9, 13, 14) . Aberrant β-catenin signaling is associated with cancer development, progression and even metastasis (9, 16, 17) . A recent study has demonstrated that tumors activate β-catenin in APCs including DCs (18). However, its role in the induction and activation of Treg responses to tumor is not known. In addition, the downstream mediator of β-catenin signaling in DCs that drives immune tolerance to tumors remains poorly understood. In our previous study with intestinal DCs, we have shown that the β-catenin pathway programs DCs to a
Materials and Methods

Mice
C57BL/6 male mice 6-12 wk of age were purchased from The Jackson Laboratory (Bar Harbor, ME). OT-II (Rag 2 . Successful cre-mediated deletion was confirmed by polymerase chain reaction (PCR) and protein expression analyses as previously described (19). TCF4 floxed mice (23) were crossed to CD11c-cre mice to generate mice with DCs deficient in TCF4 (TCF4 ΔDC ) and successful cre-mediated deletion was confirmed by PCR (19). All the mice were housed under specific pathogenfree conditions in the Laboratory Animal Services of Georgia Regents University.
Animal care protocols were approved by the Institutional Animal Care and Use Committee of Georgia Regents University.
Antibodies and reagents
Antibodies against mouse CD4 (GK1.5), CD8a (53-6. (16-10A1), CD86 (GL1), CD274 (MH5) and CD273 (TY25) were purchased from eBioscience. Non-phospho active β-catenin, β-catenin and TCF4 antibodies were obtained from Cell signaling technology. β-galactosidase (β-gal) antibody was purchased from Abcam. Retinol, all-trans retinoic acid (ATRA) (Sigma-Aldrich), retinoid acid receptor antagonists LE135 (Tacoris), LE540 (Wako, Japan), Citral (Sigma-Aldrich), JW55 (Tocris) and XAV 939 (Tocris) were dissolved in DMSO (1 mM). OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] (ISQVHAAHAEINEAGR) peptide was purchased from Anaspec.
Plasmids, cell culture, transient transfection and reporter assay
Raldh2 promoter luciferase construct was kindly provided by Dr. Ofelia M. Martínez-Estrada (24). Wild type β-catenin, dominant negative β-catenin and active β-catenin plasmids were provided by Dr. Zuoming Sun (City of Hope). Wild type (WT)-TCF4 and dominant negative TCF4 plasmids were from Addgene. 293T cells were cultured in DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. Cells (2-3×10 5 in each well of a 24 well-plate) were transfected with the Raldh2 promoter reporter plasmid (100 ng) and expression vectors (500 ng) by Lipofectamine method (Invitrogen). The total amount of transfected DNA was kept constant by adjusting the amount of the empty vector. Cells were collected after 24 h and lysed in 200 µl reporter lysis buffer and luciferase activities were measured by the Luciferase system, according to the manufacturer's instructions (Promega), and normalized against Renilla luciferase activities. "Fold Induction" represents normalized luciferase activity divided by the result of reporter-only groups.
Tumor model and in-vivo treatment
Age matched littermate controls were used for tumor studies. B16 melanoma expressing ovalbumin, clone MO4, was obtained from Dr. David Munn (Georgia Regents University, Augusta, GA, USA) (25) and EL4 lymphoma expressing ovalbumin, clone E.G7-OVA (EG7) was obtained from the American Type Culture Collection. To establish tumors, Author Manuscript Published OnlineFirst on January 7, 2015; DOI: 10.1158/0008-5472.CAN- complete medium containing OVA peptide (2 µg/ml) and TGFβ (1 ng/ml) in 96-well round-bottomed plates. After 5 days, cells were collected and analyzed by flow cytometry.
Flow cytometry analysis
To measure cytokines, single-cell suspensions from spleen, TDLN or tumor were ex vivo stimulated with phorbol 12-myristate 13-acetate (PMA)/Ionomycin and BrefedinA/monesin (eBioscience) for 6 hours at 37 °C, intracellular staining of IFN-γ and IL-10 was performed. To measure Treg or β-catenin or β-gal expression, corresponding Ab were added after permeabilization and fixation of cells(27). To detect aldehyde dehydrogenase (ALDH) activity, we used ALDEFLUOR kit (Stemcell) following the manufacturer's recommendations (27) . Flow cytometric analysis were performed using a FACS LSRII system (BD Biosciences) and the data were analyzed using FlowJo software (Ashland, OR).
Real-time PCR
Total mRNA was isolated from purified splenic, lymph node, and tumor CD11c + DCs using the Omega Total RNA Kit according to the manufacturer's protocol. cDNA was generated using the RNA to cDNA Ecodry Premix Kit (Clontech) according to the manufacturer's protocol. cDNA was used as a template for quantitative real-time PCR using SYBR Green Master Mix (Roche), and gene-specific primers (19,26). PCR analysis was performed using a MyiQ5 ICycler (BioRad). Gene expression was calculated relative to Gapdh.
Statistical analyses
Statistical analyses were performed using GraphPad Prism software. An unpaired onetailed Student's t test was used to determine statistical significance for tumor areas, 9 mRNA expression levels, Treg percentages, and cytokines released by various cell types between different groups. A P value less than 0.05 (*) was considered to be significant, a P value less than 0.01 (**) was considered to be very significant, and a P value less than 0.001 (***) was considered to be extremely significant. 
Results
:
Tumors induce expression of RA-synthesizing enzymes in DCs TME and tumor-draining lymph nodes (TDLNs) have elevated levels of RA and tumor APCs act as a major producer/source of RA (8) . Within cells, RA is produced from vitamin A (retinol) via a two-step enzymatic pathway where retinol is first oxidized to retinaldehyde (retinal) followed by conversion to RA (7) . First, we investigated whether and Aldh1a2 isoforms compared to the CLN DCs (Fig 1A, 1B) . This was unexpected because unlike intestinal DCs, peripheral DCs do not express these genes under homeostatic conditions (7) . To further validate these findings, we performed Aldh activity assay. TDLN DCs and TME DCs showed markedly increased Aldh activity compared to CLN DCs or DEAB (Aldh1 specific inhibitor)-treated DCs (Fig 1C) (Fig 2A, B) . Furthermore, addition of pan-RAR inhibitors (LE540/LE135) to the co-cultures markedly reduced the proportion of Tregs induced by TDLN DCs (Fig 2A, B) , suggesting that Treg induction is dependent on RA and the RAR/RXR-pathway. Taken together, these data demonstrate that TDLN DCs can metabolize vitamin A to RA and can drive Treg differentiation.
To investigate the in vivo role of RA in Treg induction in response to tumor, we examined the effects of pharmacological inhibition of Aldh1 activity with disulfiram as performed in our previous study (26) . WT mice implanted with MO4 tumor cells were treated with or without disulfiram and followed by adoptive transfer of naïve OT-II CD4 + T cells (Fig 2C) . Five days post-adoptive transfer, the frequency of OVA-specific (Fig. 3C) . Collectively, these data demonstrate that TME program DCs to express Aldh1a2 in a β-catenin-dependent manner.
We next investigated the downstream signaling pathways through which β-catenin can induce Aldh1 expression in DCs. The TCF family of transcription factors is one of the main downstream mediators of β-catenin signaling (9) and DCs highly express the TCF4 isoform (31). So, we tested whether tumor-induced activation of β-catenin in DCs promotes TCF/LEF-dependent gene transcription using TCF/LEF β-gal reporter mice (19). TDLN DCs from the reporter mice showed strong β-gal expression compared to CLN DCs (Fig 3D) . Consistent with this, we also observed increased expression of the β-catenin/TCF4 target gene, Axin2 in TDLN DCs compared to CLN DCs (Fig 3E) .
Taken together, our data demonstrates that activation of β-catenin induces the expression of TCF4 target genes in DCs in response to tumor. Author Manuscript Published OnlineFirst on January 7, 2015; DOI: 10.1158/0008-5472.CAN-14-2377 mutant β-catenin or TCF4 expression plasmids. Co-transfection with WT β-catenin and WT-TCF4 plasmids resulted in 10-12-fold increase of Aldh1a2 promoter activity (Fig.   3F ). Likewise, expression of active β-catenin further increased promoter activity. In contrast, expression of a dominant negative β-catenin or TCF4 markedly decreased its activity (Fig. 3F) . Consistent with these observations, deletion of TCF4 specifically in DCs resulted in decreased expression of Aldh1a2 gene in response to tumor (Fig. 3G ).
Taken together, these results clearly demonstrate that TME induces expression of activated β-catenin in DCs, which interacts with TCF4 and promotes transcriptional activation of Aldh1 gene expression.
DC-specific deletion of β-catenin limits T regulatory cell induction and tumor growth
The preceding experiments showed that tumor-associated DCs produce RA and drive T regulatory cell differentiation. So, we hypothesized that tumor-induced activation of the β-catenin/TCF pathway in DCs induces T regulatory responses and promotes immune tolerance. To test this, we monitored MO4 and EG7 tumor growth over time in mice that specifically lack β-catenin in DCs (19). Deletion of β-catenin in DCs (β-cat ΔDC ) significantly reduced tumor growth compared to that seen with WT mice (Fig. 4A, B) .
Next, we examined the effector phenotype of tumor-infiltrating lymphocytes (TILs) isolated from both groups of mice. Interestingly, we observed a significant decrease in the frequency of Foxp3 Figure 3B) . This observation is consistent with previous studies suggesting that the β-catenin pathway is not critical for DC maturation (27,32,33). Taken together, these results show that tumor-mediated activation of β-catenin in DCs limits antitumor immunity at least in part by regulating the expression levels of co-inhibitory and co-stimulatory molecules.
Tumor promotes regulatory DCs via a β-catenin/RA axis
The preceding results demonstrated that activation of β-catenin in DCs promotes T regulatory response and limits T cell effector response. So, we reasoned that tumorinduced activation of the β-catenin pathway imparts regulatory phenotype on DCs and promotes T regulatory response. Therefore, we tested the ability of TDLN DCs isolated from control-FL and β-cat (Fig 5B) .
Altogether, these data demonstrate that tumor-induced activation of β-catenin in DCs imparts regulatory phenotype and drives Treg cell differentiation. (Fig. 5D) . We also observed marked increase in the frequency of endogenous Foxp3 + CD4 + Tregs within tumors (Fig. 5D ). These data (Fig 6B, C, Supplementary Figure 4C) . Furthermore, the ratio of effector T cells to Treg cells was markedly increased within the tumor of treated mice compared to the control mice (data not shown). Consistent with this observation, XAV 939 treatment of tumor-bearing mice that had received OT-II CD4 + T cells by adoptive transfer resulted in the decrease in frequency and number of OVA-specific Treg cells within tumors (Fig   6D,E) . Consistent with the reduced Treg induction, XAV 939 treatment markedly reduced the expression of vitamin A-metabolizing enzymes (Fig 6F, Supplementary   Figure 4D ). We confirmed these findings in using another β-catenin/TCF inhibitor, JW55 (35,36) (Supplementary Figure 5) . Collectively, these data demonstrate that 
Discussion
Tumors First, the role of RA in the induction of Treg cells in the intestine and gut tolerance has been extensively studied (6,7). However, its role in tumor-induced immune tolerance is poorly understood. TME has high levels of RA, and APCs are major producers of RA (8) . Also, the signaling pathways that promote DCs to metabolize vitamin A into RA are not known. Our studies demonstrate that DCs in the TME acquire the ability to metabolize vitamin A via the activation of the β-catenin/TCF4 pathway, pathway programs DCs into an immunosuppressive state and promotes immune tolerance. TME can also modulate DC function by regulating DC activation and maturation, by regulating the expression of co-stimulatory and co-inhibitory molecules.
Our study shows that deletion of β-catenin resulted in increased expression of costimulatory molecules and decreased expression co-inhibitory molecules. This phenotype is associated with DC in an immunogenic state, resulting in enhanced anti-tumor immunity. In addition to inducing Tregs, β-catenin activation in DCs can also affect cross priming of CD8 T cell responses against tumors (18). Although β-catenin is known to suppress DC activation (7), it remains to be determined whether β-catenin directly regulates DC activation or does so indirectly via RA.
The receptor(s) on DCs or factor(s) in TME that activate β-catenin in DCs are currently not known. Emerging studies show that TME contains high levels of Wnt The role of these molecules if any in the activation of β-catenin pathway in DCs in TME is currently unknown. In addition, the downstream mediator of β-catenin signaling in DCs was not known. The present study shows that TCF4 is one of the key mediators of β-catenin signaling in DCs in TME. Upon activation, β-catenin is known to interact with other transcription factors such as PPARγ (10, 11) , Foxo (12, 13) , VDR (12, 14) and IRF3 
